288 related articles for article (PubMed ID: 24846238)
1. Cardiovascular effects of current and future anti-obesity drugs.
Comerma-Steffensen S; Grann M; Andersen CU; Rungby J; Simonsen U
Curr Vasc Pharmacol; 2014 May; 12(3):493-504. PubMed ID: 24846238
[TBL] [Abstract][Full Text] [Related]
2. [Pharmacological therapy of obesity].
Pagotto U; Vanuzzo D; Vicennati V; Pasquali R
G Ital Cardiol (Rome); 2008 Apr; 9(4 Suppl 1):83S-93S. PubMed ID: 18773755
[TBL] [Abstract][Full Text] [Related]
3. Role of glucagon-like peptide 1 receptor agonists in management of obesity.
Isaacs D; Prasad-Reddy L; Srivastava SB
Am J Health Syst Pharm; 2016 Oct; 73(19):1493-507. PubMed ID: 27521241
[TBL] [Abstract][Full Text] [Related]
4. Evolution of pharmacological obesity treatments: focus on adverse side-effect profiles.
Krentz AJ; Fujioka K; Hompesch M
Diabetes Obes Metab; 2016 Jun; 18(6):558-70. PubMed ID: 26936802
[TBL] [Abstract][Full Text] [Related]
5. GLP-1 receptor agonists for type 2 diabetes mellitus: recent developments and emerging agents.
Trujillo JM; Nuffer W
Pharmacotherapy; 2014 Nov; 34(11):1174-86. PubMed ID: 25382096
[TBL] [Abstract][Full Text] [Related]
6. Combating the dual burden: therapeutic targeting of common pathways in obesity and type 2 diabetes.
Scheen AJ; Van Gaal LF
Lancet Diabetes Endocrinol; 2014 Nov; 2(11):911-22. PubMed ID: 24731666
[TBL] [Abstract][Full Text] [Related]
7. [New therapies for type 2 diabetes mellitus].
Puig-Domingo M; Pellitero S
Med Clin (Barc); 2015 Jun; 144(12):560-5. PubMed ID: 25194974
[TBL] [Abstract][Full Text] [Related]
8. Tolerability and safety of the new anti-obesity medications.
Hainer V; Aldhoon-Hainerová I
Drug Saf; 2014 Sep; 37(9):693-702. PubMed ID: 25096956
[TBL] [Abstract][Full Text] [Related]
9. Glucagon-like peptide-1 receptor agonists and cardiovascular disease: from LEADER to EXSCEL.
Torekov SS
Cardiovasc Res; 2018 Aug; 114(10):e70-e71. PubMed ID: 30052921
[No Abstract] [Full Text] [Related]
10. Impact of weight-loss medications on the cardiovascular system: focus on current and future anti-obesity drugs.
Drolet B; Simard C; Poirier P
Am J Cardiovasc Drugs; 2007; 7(4):273-88. PubMed ID: 17696568
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic potential of Takeda-G-protein-receptor-5 (TGR5) agonists. Hope or hype?
Hodge RJ; Nunez DJ
Diabetes Obes Metab; 2016 May; 18(5):439-43. PubMed ID: 26818602
[TBL] [Abstract][Full Text] [Related]
12. Treatment of diabetes in patients with severe obesity.
Scheen AJ
Biomed Pharmacother; 2000 Mar; 54(2):74-9. PubMed ID: 10759290
[TBL] [Abstract][Full Text] [Related]
13. Synergistic metabolic benefits of an exenatide analogue and cholecystokinin in diet-induced obese and leptin-deficient rodents.
Trevaskis JL; Sun C; Athanacio J; D'Souza L; Samant M; Tatarkiewicz K; Griffin PS; Wittmer C; Wang Y; Teng CH; Forood B; Parkes DG; Roth JD
Diabetes Obes Metab; 2015 Jan; 17(1):61-73. PubMed ID: 25204356
[TBL] [Abstract][Full Text] [Related]
14. New medications for obesity management: changing the landscape of obesity treatment.
Boulghassoul-Pietrzykowska N; Franceschelli J; Still C
Curr Opin Endocrinol Diabetes Obes; 2013 Oct; 20(5):407-11. PubMed ID: 23974768
[TBL] [Abstract][Full Text] [Related]
15. Phentermine, topiramate and their combination for the treatment of adiposopathy ('sick fat') and metabolic disease.
Bays H
Expert Rev Cardiovasc Ther; 2010 Dec; 8(12):1777-801. PubMed ID: 20707765
[TBL] [Abstract][Full Text] [Related]
16. [The pharmacological treatment of obesity: past, present and future].
Simonyi G; Pados G; Medvegy M; Bedros JR
Orv Hetil; 2012 Mar; 153(10):363-73. PubMed ID: 22370224
[TBL] [Abstract][Full Text] [Related]
17. The cardiovascular safety of antiobesity drugs-analysis of signals in the FDA Adverse Event Report System Database.
Gorelik E; Gorelik B; Masarwa R; Perlman A; Hirsh-Raccah B; Matok I
Int J Obes (Lond); 2020 May; 44(5):1021-1027. PubMed ID: 32152496
[TBL] [Abstract][Full Text] [Related]
18. Future Pharmacotherapy for Obesity: New Anti-obesity Drugs on the Horizon.
Srivastava G; Apovian C
Curr Obes Rep; 2018 Jun; 7(2):147-161. PubMed ID: 29504049
[TBL] [Abstract][Full Text] [Related]
19. Diabesity: are weight loss medications effective?
Halpern A; Mancini MC
Treat Endocrinol; 2005; 4(2):65-74. PubMed ID: 15783244
[TBL] [Abstract][Full Text] [Related]
20. Update on obesity pharmacotherapy.
Bray GA; Ryan DH
Ann N Y Acad Sci; 2014 Apr; 1311():1-13. PubMed ID: 24641701
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
